AOD-9604 Cost vs. Alternatives: How This HGH Fragment Compares in Class

What AOD-9604 Actually Is and How It Works

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176 through 191) of human growth hormone, with an added tyrosine residue at its N-terminus. Researchers developed it to isolate the fat-metabolizing properties of GH from its growth-promoting and diabetogenic effects.

The peptide's mechanism centers on two simultaneous actions in adipose tissue. First, AOD-9604 stimulates lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. Second, it inhibits lipogenesis, the process by which the body converts circulating substrates into new fat. Heffernan et al. demonstrated in 2001 that chronic administration of the hGH fragment 177-191 (a closely related analog) to obese mice produced dose-dependent fat loss without altering IGF-1 levels or inducing insulin resistance 1. This dissociation from the GH receptor is the peptide's central selling point.

Unlike full-length growth hormone, AOD-9604 does not raise serum IGF-1. That distinction matters clinically. Elevated IGF-1 from exogenous GH is associated with fluid retention, carpal tunnel syndrome, arthralgias, and theoretical cancer risk over long durations. AOD-9604 sidesteps these pathways entirely because it binds to a distinct, still-incompletely-characterized receptor domain on adipocytes rather than the classical GH receptor 1.

The limitation is straightforward. Peer-reviewed human data for AOD-9604 remains sparse. A Phase IIb trial conducted by Metabolic Pharmaceuticals (now Calzada Ltd.) in the early 2000s enrolled approximately 300 obese adults. Results reported modest weight loss that did not reach the primary efficacy endpoint, and the program was discontinued. The full data from this trial were never published in a peer-reviewed journal, which leaves prescribers relying heavily on animal models and mechanistic inference.

AOD-9604 Monthly Cost Breakdown

A 30-day supply of AOD-9604 from a 503A compounding pharmacy ranges from $150 to $400, with most patients paying between $200 and $300 per month at standard dosing of 250 to 300 mcg injected subcutaneously once daily.

Several variables drive that spread. Pharmacy markup differs substantially between state-licensed compounders. Geographic location affects shipping cold-chain requirements. Concentration per vial matters: a 5 mg multi-dose vial priced at $180 lasts roughly 16 to 20 days at 250 mcg daily, while a 10 mg vial at $280 to $350 stretches to 33 to 40 days. Some telehealth platforms bundle the peptide with consultation fees, bacteriostatic water, syringes, and follow-up labs, pushing the all-in monthly cost toward $350 to $500.

AOD-9604 is not covered by any commercial insurance plan or Medicare Part D. Because the peptide lacks FDA approval, there is no NDA or ANDA on file, no branded manufacturer coupon, and no patient assistance program. Every dollar is out of pocket.

That cash-pay reality positions AOD-9604 in a specific economic niche. It appeals to patients who want an injectable peptide approach to adipose reduction but cannot afford or do not qualify for GLP-1 receptor agonists. Whether the cost-per-pound-lost justifies that positioning depends entirely on the magnitude of fat loss a given patient achieves, and the published evidence does not yet allow a reliable prediction of that number.

Head-to-Head Cost Comparison With FDA-Approved Alternatives

The table below contextualizes AOD-9604 pricing against the major pharmacological alternatives prescribed or compounded for fat reduction, listed by ascending monthly cost.

Orlistat (Alli OTC / Xenical Rx) runs $30 to $70 per month. It inhibits pancreatic lipase, blocking roughly 30% of dietary fat absorption. A meta-analysis of 16 RCTs (N=10,631) published in the BMJ found orlistat produced 2.9 kg greater weight loss than placebo at 12 months 2. Gastrointestinal side effects limit adherence in many patients.

AOD-9604 sits at $150 to $400 per month as described above.

Compounded semaglutide (503A or 503B sources) ranges from $200 to $500 per month depending on dose titration. The FDA issued warning letters to multiple compounders in 2023 and 2024 regarding semaglutide salt form discrepancies, raising safety questions about specific products 3. Patients using compounded semaglutide still benefit from the strong STEP trial data supporting the molecule's efficacy.

Tesamorelin (Egrifta SV) costs $800 to $1,200 per month and holds FDA approval specifically for HIV-associated lipodystrophy. It is a growth hormone-releasing hormone (GHRH) analog that increases endogenous GH secretion. The LIPO-010 trial (N=412) demonstrated a 15.2% reduction in visceral adipose tissue at 26 weeks versus 5.6% with placebo 4. Off-label prescribing for general visceral fat reduction is growing but not reimbursed by most plans.

Branded semaglutide (Wegovy 2.4 mg) lists at approximately $1,349 per month. The STEP-1 trial (N=1,961) showed 14.9% mean body weight reduction at 68 weeks compared with 2.4% for placebo 5. Insurance coverage varies widely. Patients with commercial plans and prior authorization approval may pay $0 to $25 through manufacturer copay cards.

Tirzepatide (Zepbound 15 mg) lists at roughly $1,060 per month. SURMOUNT-1 (N=2,539) demonstrated 22.5% mean weight loss at the highest dose over 72 weeks versus 3.1% for placebo 6. The dual GIP/GLP-1 mechanism produces the largest mean weight reductions of any currently available anti-obesity medication.

The cost-per-percentage-point of weight loss is where the comparison becomes uncomfortable for AOD-9604. Semaglutide delivers roughly 14.9% mean loss. Tirzepatide delivers 22.5%. AOD-9604's unpublished Phase IIb data suggested low-single-digit percentage losses. Even at one-third the price, the cost-effectiveness ratio may favor the GLP-1 class.

Evidence Gap: What the Research Actually Shows

The preclinical case for AOD-9604 is coherent. The clinical case is incomplete. That gap is the single most important factor any patient should weigh before choosing this peptide.

Heffernan et al. (2001) remains the most frequently cited study. In obese ob/ob mice, a 14-day course of the hGH fragment produced significant reductions in body fat without changes in lean mass, food intake, serum glucose, or IGF-1 1. A related paper from the same research group at Monash University showed the fragment did not impair glucose tolerance in normal or diabetic mice, reinforcing its separation from full-length GH metabolic effects 7.

Moving to humans, the picture thins dramatically. The Metabolic Pharmaceuticals Phase IIb trial was a multi-center, placebo-controlled study enrolling roughly 300 patients with obesity. Doses tested included oral and subcutaneous formulations. The company's 2007 ASX filing reported that the trial "did not meet its primary weight loss endpoint," though some secondary endpoints related to body composition trended favorably. No full manuscript has been published in a peer-reviewed journal.

Compare that evidence base to semaglutide's. The STEP program encompasses six large RCTs with a combined enrollment exceeding 8,000 patients. STEP-1 alone (N=1,961) ran 68 weeks and produced 14.9% mean weight loss 5. STEP-8 directly compared semaglutide 2.4 mg against liraglutide 3.0 mg over 68 weeks, showing semaglutide produced 15.8% vs. 6.4% weight loss 8. The Endocrine Society's 2024 clinical practice guideline for pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities 9.

No professional endocrinology or obesity medicine society has issued a recommendation for AOD-9604. The peptide does not appear in guidelines from the Endocrine Society, AACE, or the Obesity Medicine Association.

Regulatory Status and Compounding Risks

AOD-9604 is not FDA-approved for any indication. Patients obtain it exclusively through compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound medications based on individual prescriptions, but the finished products do not undergo FDA review for safety, efficacy, or manufacturing consistency.

The FDA's position on peptide compounding has tightened since 2023. The agency added tirzepatide to the drug shortage list and subsequently removed it, creating a narrow window during which 503A compounders could legally prepare copies. That cycle illustrated how compounding access can shift quickly based on shortage status. AOD-9604 occupies a different legal lane: because no FDA-approved version exists, compounders can prepare it as a "bulk drug substance" if it appears on the FDA's list of substances that may be used in compounding, or if they can demonstrate it meets the criteria under 503A.

Quality remains a genuine concern. A 2019 analysis published in JAMA Network Open tested 44 peptide products from compounding pharmacies and found that 11% contained <90% of the labeled dose, while 4.5% contained bacterial endotoxins 10. Patients considering AOD-9604 should verify that their pharmacy holds current state licensure, uses third-party Certificate of Analysis (COA) testing for each batch, and ideally carries voluntary PCAB accreditation.

Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has commented publicly: "The risk-benefit calculus for non-FDA-approved peptides is difficult to justify when we have multiple GLP-1 agents with thousands of patient-years of safety data. The cost savings may be real, but the evidence savings are not."

Who Might Still Consider AOD-9604

Despite the evidence gaps, specific patient profiles drive the ongoing demand for this peptide. Understanding those profiles helps contextualize the cost decision.

Patients who have tried GLP-1 receptor agonists and discontinued due to intolerable gastrointestinal side effects (nausea, vomiting, gastroparesis-like symptoms) sometimes seek AOD-9604 as a mechanistically distinct option. Because AOD-9604 does not act on GLP-1 receptors or slow gastric emptying, it avoids the GI burden that causes 5% to 15% of patients to stop semaglutide in clinical trials 5.

Cash-pay patients without insurance coverage for anti-obesity medications represent another group. A patient facing $1,349 per month for Wegovy with no coverage may view $250 per month for AOD-9604 as an acceptable trade-off, especially if they are targeting modest fat reduction (5 to 10 lbs) rather than large-scale weight loss (30+ lbs).

Patients concerned about lean mass preservation also express interest. AOD-9604's mechanism acts specifically on adipose tissue pathways. GLP-1 agonists reduce both fat and lean mass; the SELECT cardiovascular outcomes trial secondary analyses showed that approximately 39% of weight lost on semaglutide was lean mass 11. Whether AOD-9604 actually preserves lean mass in humans has not been confirmed in published trials, but the animal data showing no change in lean mass is part of the appeal 1.

The responsible clinical approach for any of these patients involves transparent informed consent: the prescriber should document that the patient understands AOD-9604 is not FDA-approved, that human efficacy data is limited, and that FDA-approved alternatives exist with stronger evidence. The American Association of Clinical Endocrinology (AACE) recommends this disclosure standard for any off-label or compounded anti-obesity therapy 12.

How AOD-9604 Mechanism Differs From GLP-1 Agonists and Growth Hormone

Three distinct pharmacological pathways compete in the injectable fat-reduction space. Each works differently, produces different side effect profiles, and carries different evidence.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) bind GLP-1 receptors in the pancreas, gut, and brain. They increase insulin secretion in a glucose-dependent manner, slow gastric emptying, and reduce appetite through hypothalamic signaling. Weight loss is primarily appetite-driven. The most common side effects are nausea (44% in STEP-1), diarrhea, vomiting, and constipation 5.

Growth hormone (somatropin) activates the GH receptor, increases IGF-1, stimulates lipolysis, and promotes anabolism. It reduces visceral fat but also raises fasting glucose, can worsen insulin resistance, and carries risks of edema, arthralgias, and carpal tunnel. Monthly costs for GH range from $500 to $3,000+ depending on brand and dose. The Endocrine Society does not recommend GH therapy for obesity in GH-sufficient adults 13.

AOD-9604 occupies a pharmacological middle ground. It retains the lipolytic C-terminal domain of GH but does not activate the GH receptor. No IGF-1 elevation. No insulin resistance. No appetite suppression either, which means patients must maintain caloric discipline independently. Think of it as a targeted adipose modulator rather than a systemic weight-loss agent.

That mechanistic profile explains both the appeal and the limitation. AOD-9604 may reduce fat in a specific compartment without systemic metabolic disruption. But it does not suppress the hunger drive that underlies most patients' caloric surplus. For the majority of patients with obesity defined by BMI ≥30, appetite regulation is the primary therapeutic need, and GLP-1 agonists address it directly.

The Bottom Line on Value

Cost comparisons without efficacy context are misleading. A $200-per-month peptide that produces 2% body weight reduction is not cheaper than a $1,000-per-month drug that produces 15% to 22%. The metric that matters is cost per clinically meaningful outcome.

The threshold for "clinically meaningful" weight loss, per FDA guidance and the Endocrine Society, is ≥5% of baseline body weight sustained for ≥12 months 9. Semaglutide 2.4 mg gets 86.4% of patients past that threshold at 68 weeks. Tirzepatide at 15 mg gets 96%. AOD-9604's human success rate at that endpoint is unknown because the data was never published.

Patients should ask their prescriber three questions before starting AOD-9604: What specific outcome should I expect at 12 weeks? How will we measure whether this is working (DEXA, waist circumference, weight)? And at what point do we switch to an evidence-based alternative if it is not?